Detalles de la búsqueda
1.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394384
2.
Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients.
J Psychosoc Oncol
; 37(4): 427-440, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30798774
3.
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
J Urol
; 199(2): 459-464, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867562
4.
Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment.
Psychooncology
; 26(5): 632-639, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27338029
5.
The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients.
J Psychosoc Oncol
; 35(6): 741-757, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28816636
6.
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Lancet Oncol
; 15(6): 592-600, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24739897
7.
Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment.
Psychooncology
; 23(10): 1172-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24729471
8.
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
Eur Urol Open Sci
; 45: 12-22, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36353661
9.
Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study.
J Geriatr Oncol
; 11(2): 320-326, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31619371
10.
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Eur Urol
; 74(1): 37-45, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28844372
11.
The use of uHear™ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment.
Acta Clin Belg
; 73(2): 132-138, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063810
12.
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Clin Genitourin Cancer
; 15(4): 502-508, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28258960
13.
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Urol Oncol
; 34(6): 254.e7-254.e13, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26850781
14.
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 34(22): 2636-43, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27298414
15.
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Eur Urol
; 68(5): 787-94, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25687533
16.
FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Eur Urol
; 57(4): 641-7, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19477579
Resultados
1 -
16
de 16
1
Próxima >
>>